Golgi fragmentation – One of the earliest organelle phenotypes in Alzheimer’s disease neurons
暂无分享,去创建一个
J. Gorodkin | S. Cirera | N. Doncheva | M. Larsen | H. Wandall | P. Jensen | M. Meyer | Shekhar Kedia | Veerendra P. Gadekar | A. Simonsen | Ravi S Muddashetty | T. Nielsen | K. Freude | P. Hyttel | N. de Haan | B. Aldana | Frederik Ravnkilde Marlet | Henriette Haukedal | J. E. Nielsen | Anna Poon | Carlota Pires | Pernille Schiønning | Sarah Vallin | Fawzi Khoder Agha | G. Corsi | Deepak Nair | Abinaya Chandrasekaran
[1] Nadezhda T. Doncheva,et al. The transcriptomic landscape of neurons carrying PSEN1 mutations reveals changes in extracellular matrix components and non-coding gene expression , 2022, Neurobiology of Disease.
[2] H. Wandall,et al. In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography–Mass Spectrometry and Glycogenomics , 2022, Analytical chemistry.
[3] A. Wingo,et al. Large‐scale deep multi‐layer analysis of Alzheimer’s disease brain reveals strong proteomic disease‐related changes not observed at the RNA level , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[4] D. Campion,et al. Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease , 2021, Acta Neuropathologica Communications.
[5] H. Tanila,et al. Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer’s disease , 2021, Cell Death & Disease.
[6] A. Wingo,et al. Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level , 2021, Nature Neuroscience.
[7] C. Mannella,et al. Effect of crista morphology on mitochondrial ATP output: A computational study , 2021, Current research in physiology.
[8] K. Freude,et al. Implications of Glycosylation in Alzheimer’s Disease , 2021, Frontiers in Neuroscience.
[9] A. Mahadevan,et al. Alteration in synaptic nanoscale organization dictates amyloidogenic processing in Alzheimer's disease , 2020, iScience.
[10] Hui Peng,et al. Identification of SCARA3 with potential roles in metabolic disorders , 2020, Aging.
[11] E. Gazit,et al. Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration , 2020, Cellular and Molecular Life Sciences.
[12] J. Sibarita,et al. Real-time nanoscale organization of amyloid precursor protein. , 2020, Nanoscale.
[13] R. Tanzi,et al. Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease , 2020, Nature Communications.
[14] Michael J MacCoss,et al. Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics. , 2020, Journal of proteome research.
[15] Oliver C. Grant,et al. O-glycosylation on cerebrospinal fluid and plasma Apolipoprotein E differs in the lipid binding domain. , 2019, Glycobiology.
[16] Pei-Pei Liu,et al. History and progress of hypotheses and clinical trials for Alzheimer’s disease , 2019, Signal Transduction and Targeted Therapy.
[17] M. Larsen,et al. Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation , 2019, Neurobiology of Disease.
[18] E. Martínez-Alonso,et al. Golgi Fragmentation in Neurodegenerative Diseases: Is There a Common Cause? , 2019, Cells.
[19] Erpan Ahat,et al. Golgi Structure and Function in Health, Stress, and Diseases , 2019, Results and problems in cell differentiation.
[20] M. Filius,et al. Highly sensitive CE-ESI-MS analysis of N-glycans from complex biological samples , 2019, Nature Communications.
[21] Ravi S Muddashetty,et al. Generation of two iPSC lines with either a heterozygous V717I or a heterozygous KM670/671NL mutation in the APP gene. , 2019, Stem cell research.
[22] P. Gleeson,et al. The trans-Golgi network is a major site for α-secretase processing of amyloid precursor protein in primary neurons , 2018, The Journal of Biological Chemistry.
[23] Mark Gerstein,et al. GENCODE reference annotation for the human and mouse genomes , 2018, Nucleic Acids Res..
[24] P. Alifragis,et al. Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention , 2018, Neural regeneration research.
[25] N. Taniguchi,et al. N-glycan and Alzheimer's disease. , 2017, Biochimica et biophysica acta. General subjects.
[26] A. Larsen,et al. Sortilin-Related Receptor Expression in Human Neural Stem Cells Derived from Alzheimer's Disease Patients Carrying the APOE Epsilon 4 Allele , 2017, Neural plasticity.
[27] Jordan A. Ramilowski,et al. An atlas of human long non-coding RNAs with accurate 5′ ends , 2017, Nature.
[28] J. DeFelipe,et al. Morphometric alterations of Golgi apparatus in Alzheimer's disease are related to tau hyperphosphorylation , 2017, Neurobiology of Disease.
[29] Yigong Shi,et al. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase , 2016, Proceedings of the National Academy of Sciences.
[30] W. M. van der Flier,et al. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity , 2016, Journal of Alzheimer's disease : JAD.
[31] T. Nielsen,et al. Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer's disease patient carrying a L150P mutation in presenilin 1. , 2016, Stem cell research.
[32] Stefan J. Kempf,et al. Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics , 2016, Neural regeneration research.
[33] G. Waldemar,et al. Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1. , 2016, Stem cell research.
[34] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[35] G. Waldemar,et al. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1. , 2016, Stem cell research.
[36] M. Bekier,et al. Golgi fragmentation in Alzheimer's disease , 2015, Front. Neurosci..
[37] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[38] C. Cotman,et al. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease , 2014, Neurobiology of Aging.
[39] Z. Tümer,et al. Transient p53 Suppression Increases Reprogramming of Human Fibroblasts without Affecting Apoptosis and DNA Damage , 2014, Stem cell reports.
[40] L. Tan,et al. The Role of SORL1 in Alzheimer’s Disease , 2014, Molecular Neurobiology.
[41] Yanzhuang Wang,et al. Aβ-induced Golgi fragmentation in Alzheimer’s disease enhances Aβ production , 2014, Proceedings of the National Academy of Sciences.
[42] J. Ávila,et al. Deconstructing Mitochondrial Dysfunction in Alzheimer Disease , 2013, Oxidative medicine and cellular longevity.
[43] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[44] T. Lehtimäki,et al. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort , 2013, PloS one.
[45] Pelin Yilmaz,et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..
[46] Rene Ranzinger,et al. The GlycanBuilder and GlycoWorkbench glycoinformatics tools: updates and new developments , 2012, Biological chemistry.
[47] F. J. Livesey,et al. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks , 2012, Nature Protocols.
[48] Wei Li,et al. RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..
[49] B. Lu,et al. Synapses and Dendritic Spines as Pathogenic Targets in Alzheimer's Disease , 2012, Neural plasticity.
[50] J. Nyengaard,et al. Retromer Binds the FANSHY Sorting Motif in SorLA to Regulate Amyloid Precursor Protein Sorting and Processing , 2012, The Journal of Neuroscience.
[51] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[52] André M Deelder,et al. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. , 2011, Analytical chemistry.
[53] S. Faraone,et al. Review Article: Genetics of Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.
[54] A. Kakita,et al. Increased Levels of Soluble LR11 in Cerebrospinal Fluid of Patients with Alzheimer Disease , 2010, Dementia and Geriatric Cognitive Disorders.
[55] A. Levey,et al. Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease , 2008, The Journal of Neuroscience.
[56] M. Molinari,et al. Consequences of individual N-glycan deletions and of proteasomal inhibition on secretion of active BACE. , 2008, Molecular biology of the cell.
[57] M. Pool,et al. NeuriteTracer: A novel ImageJ plugin for automated quantification of neurite outgrowth , 2008, Journal of Neuroscience Methods.
[58] A. Fagan,et al. Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation , 2007, Annals of neurology.
[59] K. Lunetta,et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.
[60] C. van Broeckhoven,et al. Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.
[61] Hirohisa Tajima,et al. Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. , 2006, Current neuropharmacology.
[62] Theo Wallimann,et al. Mitochondrial creatine kinase in human health and disease. , 2006, Biochimica et biophysica acta.
[63] Irwin D Kuntz,et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[64] B. Hyman,et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[65] Robert S. Balaban,et al. Mitochondria, Oxidants, and Aging , 2005, Cell.
[66] I. Grundke‐Iqbal,et al. Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.
[67] P. Greengard,et al. Presenilin-1 Regulates Intracellular Trafficking and Cell Surface Delivery of β-Amyloid Precursor Protein* , 2003, The Journal of Biological Chemistry.
[68] M. Farquhar,et al. Cell type-dependent variations in the subcellular distribution of alpha- mannosidase I and II , 1993, The Journal of cell biology.
[69] E. Reynolds. THE USE OF LEAD CITRATE AT HIGH pH AS AN ELECTRON-OPAQUE STAIN IN ELECTRON MICROSCOPY , 1963, The Journal of cell biology.
[70] OUP accepted manuscript , 2021, Nucleic Acids Research.
[71] G. Waldemar,et al. Lab resource: Stem cell lineGeneration of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a L150P mutation in PSEN-1 , 2016 .
[72] N. Taniguchi,et al. Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions. , 2016, The Biochemical journal.
[73] Stavros J. Baloyannis. Golgi apparatus and protein trafficking in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[74] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[75] A. Deelder,et al. HILIC SPE microtips for micro-scale purification and enrichment of glycans and glycopeptides , 2012 .
[76] George Perry,et al. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.
[77] Mark S. Shearman,et al. Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .
[78] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .